Holen Sie sich die Stockscreener-App
1.62
9.46%
0.14
Handel nachbörslich:
1.65
0.03
+1.85%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ONCT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.48
Offen:
$1.51
24-Stunden-Volumen:
136.92K
Relative Volume:
1.71
Marktkapitalisierung:
$4.77M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-39.48M
KGV:
-2.1316
EPS:
-0.76
Netto-Cashflow:
$-32.16M
1W Leistung:
+5.88%
1M Leistung:
+29.60%
6M Leistung:
-81.48%
1J Leistung:
-77.50%
1-Tages-Spanne:
$1.50
$1.68
1-Wochen-Bereich:
$1.41
$1.68
52-Wochen-Spanne:
$1.05
$13.14
Oncternal Therapeutics Inc Stock (ONCT) Company Profile
Firmenname
Oncternal Therapeutics Inc
Sektor
Branche
Telefon
(858) 434-1113
Adresse
12230 EL CAMINO REAL, SAN DIEGO, CA
Oncternal Therapeutics Inc Stock (ONCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-07 | Eingeleitet | Oppenheimer | Outperform |
| 2021-02-23 | Eingeleitet | Northland Capital | Outperform |
Oncternal Therapeutics Inc Aktie (ONCT) Neueste Nachrichten
StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World
Oncternal Therapeutics, Inc. Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - Marketscreener.com
Oncternal reports positive prostate cancer treatment results By Investing.com - Investing.com Australia
Oncternal reports positive prostate cancer treatment results - Investing.com India
Oncternal Therapeutics Announces Updated Safety and - GlobeNewswire
Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - Yahoo Finance
B-Cell Non-Hodgkin Lymphoma Pipeline Assessment 2024: Therapies, Clinical Trials, and Growth Prospects | Biegene, Oncternal Therapeutics, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc., Autolus - Barchart
Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com - Defense World
ONCT Stock Touches 52-Week Low at $1.19 Amid Market Challenges - Investing.com Australia
Oncternal Therapeutics Inc (ONCT) Q2 2024 Earnings Call Highlights: Advancements in Clinical ... - Yahoo Finance Australia
Oncternal stock jumps 9% on FDA fast track designation - MSN
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.58% - MSN
ONCT Stock Touches 52-Week Low at $1.31 Amid Market Challenges - Investing.com Australia
ONCT Stock Touches 52-Week Low at $1.31 Amid Market Challenges By Investing.com - Investing.com South Africa
Recent Research Analysts’ Ratings Changes for Oncternal Therapeutics (ONCT) - Defense World
Omnicell Appoints Nnamdi Njoku as New COO - TipRanks
Oncolytics Biotech (TSE:ONC) Reaches New 12-Month Low at $1.20 - Defense World
ONON’s Stock Market Adventure: 85.15% YTD Growth Amidst Volatility - The InvestChronicle
Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer - Silicon UK
ONMD’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Levi & Korsinsky Notifies Shareholders of Outset Medical, - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Outset Medical, Inc.OM - PR Newswire
Fred Alger Management LLC Has $44.73 Million Position in On Holding AG (NYSE:ONON) - MarketBeat
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace
Recent Insider Activity Suggests Potential Gains for Outset Medical Inc (OM) - Knox Daily
On Holding's Options Frenzy: What You Need to Know - Benzinga
This Option Provides Gains By Coasting With On Running Shoes - Investor's Business Daily
ONON’s valuation metrics: A comprehensive analysis - US Post News
OM Stock on the Rise: A Promising Investment - The InvestChronicle
Was Outset Medical Inc (OM)’s session last reading good? - US Post News
Promising Progress in Oncology as Cancer Deaths Decline and Research Grows - Baystreet.ca
Views of Wall Street’s Leading Experts on Onconetix Inc - SETE News
Financial Metrics Unveiled: Outset Medical Inc (OM)’s Key Ratios in the Spotlight - The Dwinnex
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com - Defense World
Outset Medical (OM) Shares Down 94% Since Disclosing FDA - GlobeNewswire
On Holding Options Trading: A Deep Dive into Market Sentiment - Benzinga
ON (NYSE:ONON) Rating Increased to Neutral at Bank of America - MarketBeat
OM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Outset Medical, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Onsemi Could Be Set Up For a Solid Rebound: Here's Why - MarketBeat
Kayne Anderson Rudnick Investment Management LLC Boosts Stock Position in On Holding AG (NYSE:ONON) - MarketBeat
Onconetix (NASDAQ:ONCO) Shares to Reverse Split on Tuesday, September 24th - Defense World
Bradley Foster & Sargent Inc. CT Increases Stock Position in On Holding AG (NYSE:ONON) - Defense World
Onsemi (NASDAQ:ON) Holdings Raised by Argent Trust Co - Defense World
Why Onconetix (ONCO) Shares Are Down 27% - Benzinga
Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders - GlobeNewswire
On Holding AG (NYSE:ONON) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Oncolytics Biotech reports positive results from breast cancer study | 2024-09-19 | Investing News - Stockhouse Publishing
Recent Breakthroughs in Cancer Research Could Impact These Key Companies - Baystreet.ca
Oncolytics Phase 2 breast cancer data ‘compelling, says H.C. Wainwright - TipRanks
Oncolytics Biotech Inc - Baystreet.ca
Finanzdaten der Oncternal Therapeutics Inc-Aktie (ONCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oncternal Therapeutics Inc-Aktie (ONCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wills Robert James | Director |
Apr 08 '24 |
Buy |
8.96 |
3,086 |
27,655 |
10,000 |
| Wills Robert James | Director |
Mar 28 '24 |
Buy |
8.48 |
6,914 |
58,602 |
6,914 |
| HALE DAVID F | Director |
Feb 23 '24 |
Buy |
9.04 |
714 |
6,455 |
714 |
| HALE DAVID F | Director |
Feb 23 '24 |
Buy |
9.04 |
266 |
2,405 |
29,673 |
| Wills Robert James | Director |
Feb 23 '24 |
Sale |
9.04 |
980 |
8,859 |
0 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):